Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Losartan conferred significant renal benefits in patients with type 2 diabetes and nephropathy, and it was generally well tolerated.
COVID-19 and Italy: what next?
Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype.
- M. Noris, J. Caprioli, G. Remuzzi
- Medicine, BiologyClinical journal of the American Society of…
- 1 October 2010
Results underline the need of genetic screening for all susceptibility factors as part of clinical management of aHUS and for identification of patients who could safely benefit from kidney transplant.
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global…
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases.
Interventions targeting CKD, particularly to reduce urine protein excretion, are efficacious, cost-effective methods of improving cardiovascular and renal outcomes, especially when applied to high-risk groups and Integration of these approaches within NCD programs could minimize the need for renal replacement therapy.
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
Nonfamilial thrombotic throm bocytopenic purpura is due to an inhibitor of von Willebrand factor-cleaving protease, whereas the familial form seems to be caused by a constitutional deficiency of the protease.
Delayed graft function in kidney transplantation
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke.
Atypical hemolytic-uremic syndrome.
Current concepts about the pathobiology of atypical hemolytic–uremic syndrome are reviewed and its diagnosis and management are reviewed.